Could Promising Cancer-Fighting CAR-T Cell Therapy Cause 'Brain Fog'?
Click to start listening
Synopsis
A groundbreaking study reveals that while CAR-T cell therapy offers hope in cancer treatment, it could also bring about cognitive challenges such as forgetfulness and concentration issues. This dual impact highlights the need for thorough understanding and management of long-term effects in immunotherapy.
Key Takeaways
- CAR-T cell therapy is a promising cancer treatment.
- It may cause mild cognitive impairments such as brain fog.
- These cognitive effects are linked to mechanisms similar to those seen in chemotherapy.
- Understanding long-term effects is crucial for developing effective therapeutic strategies.
- Medications targeting cognitive issues could enhance recovery.
New Delhi, May 13 (NationPress) While CAR-T cell therapy has demonstrated significant potential in combating cancer, a recent study indicates it may also result in cognitive issues such as 'brain fog', characterized by forgetfulness and concentration difficulties.
CAR-T cell therapy is a form of immunotherapy that involves genetically modifying a patient’s T cells to enhance their ability to identify and attack cancer cells in the bloodstream.
The research, spearheaded by a team from Stanford University, revealed that this therapy can lead to mild cognitive impairments regardless of other cancer treatments.
Interestingly, the same biological mechanism that causes cognitive decline from chemotherapy and respiratory illnesses like COVID-19 is also at work here.
“CAR-T cell therapy is incredibly promising: We are witnessing long-term survivors after treatment for aggressive cancers, saving lives that would otherwise have been lost,” stated Michelle Monje, a Professor in Pediatric Neuro-Oncology at Stanford Medicine.
“It is essential to understand all potential long-term effects, including this newly identified syndrome of immunotherapy-related cognitive impairment, so we can devise therapeutic strategies to address it,” Monje added.
The findings, published in the journal Cell, involved studying mice with tumors induced in various locations: brain, blood, skin, and bone.
The researchers aimed to analyze how location and the immune response influenced cognition post CAR-T cell treatment.
Standard cognitive tests were conducted on the mice before and after treatment, assessing their responses to novel objects and their ability to navigate simple mazes.
Results showed that CAR-T therapy led to mild cognitive impairment in mice with tumors originating in, spreading to, and located outside the brain. The only mice that did not exhibit cognitive issues post-treatment were those with bone cancer, which caused minimal inflammation alongside the cancer-fighting efforts of the CAR-T cells.
The study pinpointed microglia, the brain's immune cells, as crucial players in this cognitive decline.
Moreover, the researchers proposed strategies to remedy these cognitive challenges.
Medications aimed at reducing brain fog may facilitate better recovery from cancer immunotherapies, according to the research team.
Point of View
Understanding these potential cognitive impacts is essential for patient management and therapeutic development.
NationPress
09/06/2025
Frequently Asked Questions
What is CAR-T cell therapy?
CAR-T cell therapy is an advanced form of immunotherapy that modifies a patient's T cells to better recognize and eliminate cancer cells.
What are the cognitive effects associated with CAR-T cell therapy?
The therapy may lead to mild cognitive impairments, including brain fog, forgetfulness, and difficulty concentrating.
How does CAR-T therapy compare to traditional cancer treatments?
Unlike traditional treatments such as chemotherapy, CAR-T therapy utilizes the body's immune system to target cancer, potentially leading to more effective outcomes.
What did the study conducted by Stanford University reveal?
The study found that CAR-T cell therapy can result in cognitive impairments similar to those caused by chemotherapy and respiratory infections.
What strategies were proposed to address cognitive issues from CAR-T therapy?
Researchers suggested medications that target brain fog to help improve recovery from cancer immunotherapies.
